Last updated: 2026-09-24 02:34:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Acadia Pharmaceuticals Inc. (ACAD) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $25.43, with a market capitalization of $4.55B and a P/E ratio of 11.96. Over the past 52 weeks, its price has ranged from $19.69 to $30.96. This page covers its latest market performance, valuation, price trends and company information.
$4.55B | |
$26.41 | |
$58.72 | |
$0.65 | |
$26.41 | |
1.05M | |
1.70M | |
11.96 | |
$30.96 | |
$19.69 | |
-- | |
-- |
Acadia Pharmaceuticals Inc. (ACAD) last closed at $26.41 as of 2026-09-23 23:31:00, unchanged from the previous close of $26.41.
During the latest regular trading session, ACAD traded between $0.65 and $58.72, with a volume of 1.05M shares. The closing price was near the middle and near the middle of its 52-week range.
Over the past seven days, Acadia Pharmaceuticals Inc. (ACAD) moved from $27.52 to $25.43, representing a decline of 7.61% ($2.09).
The stock traded between $24.94 and $28.10 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.97 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 50.9%
ACAD is currently trading at $25.43, placing it 50.9% of the way from its 52-week low of $19.69 to its 52-week high of $30.96. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 798 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Acadia Pharmaceuticals Inc. (ACAD) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.